Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that participants with HPV positive and hypoxia
negative T1-2, N1-2c (AJCC, 7th ed.) oropharyngeal squamous cell carcinoma receiving a major
de-escalated radiation therapy with 2 cycles of standard chemotherapy is not inferior to
comparable subjects treated with the current standard chemoradiation.
Accrual for Cohort A has been completed.
Cohort B is active and continues to enroll participants where surgery is optional and proton
is allowed.